BOX Stock Chart & Stats
€163.35
€0.00(0.00%)
At close: 4:00 PM EDT
€163.35
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€122.15 - €179.95
Previous CloseN/A
Volume0.00
Average Volume (3M)30.00
Market Cap
€45.88B
Enterprise Value€57.58B
Total Cash (Recent Filing)€709.00M
Total Debt (Recent Filing)€16.81B
Price to Earnings (P/E)58.4
Beta0.49
Next Earnings
Nov 05, 2026EPS Estimate
3.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.32
Shares Outstanding272,386,800
10 Day Avg. Volume84
30 Day Avg. Volume30
Financial Highlights & Ratios
PEG Ratio-37.04
Price to Book (P/B)1.66
Price to Sales (P/S)1.93
P/FCF Ratio15.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€171.02Price Target Upside4.70% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)11.82
Revenue Forecast (FY)€17.57B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables And Workflow IntegrationBD’s recurring consumables model supports repeat purchasing across routine clinical and laboratory workflows. Customer relationships, product standardization and switching costs can reinforce retention, providing a durable revenue base that is less dependent on one-time equipment sales.
Operational Execution And Cash-flow ImprovementRecent execution shows that productivity and mix benefits are translating into stronger earnings and cash generation. The raised FY26 EPS outlook, 25% operating-margin target and improved free cash flow provide support for continued investment and shareholder returns.
Expanded Domestic Manufacturing PlatformThe planned U.S. investment could strengthen BD’s domestic production footprint and resilience for essential medical consumables. Expanding end-to-end manufacturing may improve strategic positioning with healthcare customers, while broader domestic capacity supports long-term market access.
Bears Say
Recent Revenue And Net-margin ContractionThe recent deterioration in revenue and net margin indicates that BD’s otherwise stable operating model is facing weaker growth and bottom-line conversion. If sustained, this could reduce internal funding capacity and constrain the pace of reinvestment or earnings recovery.
Leverage Remains Above The Company TargetLeverage above the stated target limits financial flexibility even though cash generation remains positive. Debt reduction may compete with repurchases, dividends and growth investment, while a higher balance-sheet burden can make future execution more sensitive to operating setbacks.
Defined FY27 Alaris And Tariff HeadwindsThe Alaris remediation creates a visible medium-term drag on revenue, while tariffs and related cost exposure are pressuring margins. Management expects pricing and productivity to offset these effects, but the headwinds still make near-term growth and margin expansion less predictable.
BOX FAQ
What was Becton Dickinson And Company’s price range in the past 12 months?
Becton Dickinson And Company lowest stock price was €122.15 and its highest was €179.95 in the past 12 months.
What is Becton Dickinson And Company’s market cap?
Becton Dickinson And Company’s market cap is €45.88B.
When is Becton Dickinson And Company’s upcoming earnings report date?
Becton Dickinson And Company’s upcoming earnings report date is Nov 05, 2026 which is in 19 days.
How were Becton Dickinson And Company’s earnings last quarter?
Becton Dickinson And Company released its earnings results on Aug 06, 2026. The company reported €2.88 earnings per share for the quarter, beating the consensus estimate of €2.801 by €0.079.
Is Becton Dickinson And Company overvalued?
According to Wall Street analysts Becton Dickinson And Company’s price is currently Undervalued.
Does Becton Dickinson And Company pay dividends?
Becton Dickinson And Company does not currently pay dividends.
What is Becton Dickinson And Company’s EPS estimate?
Becton Dickinson And Company’s EPS estimate is 3.63.
How many shares outstanding does Becton Dickinson And Company have?
Becton Dickinson And Company has 272,386,800 shares outstanding.
What happened to Becton Dickinson And Company’s price movement after its last earnings report?
Becton Dickinson And Company reported an EPS of €2.88 in its last earnings report, beating expectations of €2.801. Following the earnings report the stock price went up 5.326%.
Which hedge fund is a major shareholder of Becton Dickinson And Company?
Currently, no hedge funds are holding shares in DE:BOX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Becton Dickinson Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€171.02 (4.70% Upside)
€171.02 (4.70% Upside)
Blogger Sentiment
Bullish
DE:BOX Sentiment 77%
Sector Average 66%
Sector Average 66%
Insider Transactions
Sold Shares
Worth €1.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
35.31%
12-Months-Change
Fundamentals
Return on Equity
3.79%
Trailing 12-Months
Asset Growth
-7.60%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Becton Dickinson And Company
Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.
BOX Company Deck
BOX Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong execution across BD's focused med‑tech portfolio: revenue and adjusted EPS beat expectations, growth platforms showed double-digit expansion, productivity and cash flow improved materially, and the company raised EPS guidance. Headwinds are defined and manageable — chiefly Alaris remediation, tariffs, vaccine weakness in China and some margin pressure versus the prior year — and management laid out clear mitigation actions (pricing, productivity, commercial investments, AI for supply chain). Overall the positives materially outweigh the negatives.View all DE:BOX earnings summariesBOX Revenue Breakdown
52.45% Medical
23.66% Life Sciences
23.89% Interventional

BOX Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
€171.02
▲(4.70% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Baxter International
―
ICU Medical
―
Teleflex
―
West Pharmaceutical Services
―
Medline
―












